Could an Immune-Boosting herb improve colorectal cancer survival?
NCT ID NCT07703709
First seen Jul 14, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study looks at whether adding an immune-modulating drug called Astragalus polysaccharide (APS) to standard cancer treatments can help people with colorectal cancer live longer. The drug is already approved in Taiwan for cancer-related fatigue. Researchers will review medical records of 60 patients to compare outcomes between those who received APS plus standard therapy and those who received standard therapy alone. The goal is to see if APS improves overall survival and other measures like disease-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an immunomodulator called Astragalus polysaccharide (APS) Injection
- What this could lead to
- If adding APS to standard therapy improves survival, it could offer a new, well-tolerated option for colorectal cancer treatment.
- What could go wrong
- This is a real-world study, not a randomized trial, so results may be influenced by patient selection. The benefit of APS in colorectal cancer is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Cheng Ching General Hospital, Chung Kang Branch
RECRUITINGTaichung, 40764, Taiwan
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices